Brokerages Anticipate Aileron Therapeutics, Inc. (NASDAQ:ALRN) to Announce -$0.09 EPS

Equities analysts expect Aileron Therapeutics, Inc. (NASDAQ:ALRNGet Rating) to post earnings per share of ($0.09) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aileron Therapeutics’ earnings. Aileron Therapeutics reported earnings per share of ($0.06) in the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The company is expected to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Aileron Therapeutics will report full-year earnings of ($0.38) per share for the current year, with EPS estimates ranging from ($0.39) to ($0.37). For the next year, analysts forecast that the company will report earnings of ($0.39) per share, with EPS estimates ranging from ($0.39) to ($0.38). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that follow Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRNGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01).

Several research analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of Aileron Therapeutics in a research report on Tuesday, March 29th. William Blair reiterated an “outperform” rating on shares of Aileron Therapeutics in a research report on Tuesday, March 29th. Finally, Zacks Investment Research lowered Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 12th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. KCK LTD. purchased a new stake in Aileron Therapeutics in the fourth quarter valued at $362,000. Blair William & Co. IL raised its position in Aileron Therapeutics by 32.9% in the fourth quarter. Blair William & Co. IL now owns 1,067,489 shares of the company’s stock valued at $601,000 after purchasing an additional 264,329 shares during the period. Bailard Inc. purchased a new stake in Aileron Therapeutics in the first quarter valued at $66,000. Acadian Asset Management LLC purchased a new stake in Aileron Therapeutics in the fourth quarter valued at $47,000. Finally, Envestnet Asset Management Inc. raised its position in Aileron Therapeutics by 152.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 136,760 shares of the company’s stock valued at $77,000 after purchasing an additional 82,584 shares during the period. 37.06% of the stock is currently owned by institutional investors.

ALRN stock remained flat at $$0.44 during trading on Friday. The company had a trading volume of 113,832 shares, compared to its average volume of 317,420. The stock’s 50-day moving average is $0.49 and its 200-day moving average is $0.53. The firm has a market capitalization of $39.96 million, a P/E ratio of -1.47 and a beta of 2.50. Aileron Therapeutics has a 52 week low of $0.32 and a 52 week high of $1.40.

Aileron Therapeutics Company Profile (Get Rating)

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.

See Also

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.